The epidemiology of anxiety disorders: a review by Martin, Patrick
nxiety is a common psychiatric disorder.
1 It is
usually associated with fear,nervousness,apprehension,
and panic, but may also involve the cardiovascular, res-
piratory, gastrointestinal, or nervous systems, individu-
ally or in combination.
2
Anxiety has been recognized as a symptom for centuries.
However,it was only recently,with the incorporation of
Klein’s
3 conceptualization of panic disorder (PD) as a sep-
arate entity into Diagnostic and Statistical Manual of
Mental Disorders, Third Edition
4 and  Revised Third
Edition
5 (DSM-III and DSM-III-R) that anxiety states
began to be subdivided into distinct entities such as PD
with and without agoraphobia,social phobia (SP),post-
traumatic stress disorder (PTSD),obsessive-compulsive
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Epidemiological studies show that anxiety disorders are highly prevalent and an important cause of functional impairment;
they constitute the most frequent mental disorders in the community. Phobias are the most common with the highest rates
for simple phobia and agoraphobia. Panic disorder (PD) and obsessive-compulsive disorder (OCD) are less frequent (2% life-
time prevalence), and there are discordant results for social phobia (SP) (2%-16%) and generalized anxiety disorder (GAD)
(3%-30%). These studies underline the importance of an accurate definition of disorders using unambiguous diagnostic and
assessment criteria. The boundaries between anxiety disorders are often ill defined and cases may vary widely according to
the definition applied. Simple phobia, agoraphobia, and GAD are more common in women, while there is no gender differ-
ence for SP, PD, and OCD. Anxiety disorders are more common in separated, divorced, and widowed subjects; their preva-
lence is highest in subjects aged 25 to 44 years and lowest in subjects aged >65 years. The age of onset of the different types
of anxiety disorders varies widely: phobic disorders begin early in life, whereas PD occurs in young adulthood. Clinical—rather
than epidemiological—studies have examined risk factors such as life events, childhood experiences, and familial factors.
Anxiety disorders have a chronic and persistent course, and are frequently comorbid with other anxiety disorders, depressive
disorders, and substance abuse. Anxiety disorders most frequently precede depressive disorders or substance abuse. Comorbid
diagnoses may influence risk factors like functional impairment and quality of life. It remains unclear whether certain anxi-
ety disorders (eg, PD) are risk factors for suicide. The comorbidity of anxiety disorders has important implications for assess-
ment and treatment, and the risk factors should be explored. The etiology, natural history, and outcome of these disorders
need to be further addressed in epidemiological studies.
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The epidemiological approach to the study of anxiety
disorders is associated with certain strengths and weak-
nesses. Epidemiological studies are very informative
because they gather data from large numbers of subjects,
use powerful statistical techniques, and survey commu-
nity samples of people who are not in treatment.The
study of large numbers of subjects allows for compar-
isons across relevant groups based on differences in gen-
der,race,education,occupation,ethnicity,and other fac-
tors.Large numbers also provide the statistical power to
use sophisticated analytical strategies,such as multivari-
ate regression analysis, which can dissect the effects of
complex sociodemographic variables. Community sur-
veys can sample nonclinical populations, leading to the
investigation of many variables without the confound-
ing factor of treatment seeking, which is strongly influ-
enced by gender, education, and other sociodemo-
graphic and cultural factors.
Epidemiological studies have limitations in their capac-
ity to answer certain questions about anxiety disorders.
Complex sociodemographic variables, such as gender,
race, education, ethnicity, language, and religion, are
measured in epidemiological surveys in an attempt to
identify some of the factors that may influence psychi-
atric symptom formation.
The ever-increasing attention paid to anxiety disorders
is rooted in evidence that anxiety disorders are forms of
mental disorders that obviously start early in life, and
negatively affect school and work performance, as well
as later psychosocial functioning, much more than pre-
viously thought.Furthermore,the traditional belief that
most anxieties are short in duration and remit sponta-
neously has not been confirmed. On the contrary, the
few prospective studies on course and outcome suggest
that anxiety disorders belong to the most chronic forms
of mental disorders. More recent epidemiological stud-
ies try to identify the mechanism involved in the persis-
tence and chronicity of these disorders, as well as to
quantify the degree of associated suffering and impair-
ments. Another important trend in epidemiological
research is that the critical role of anxiety disorders in
primary care is now being acknowledged.Thus,attempts
have been made to specify in detail how frequently anx-
iety disorders are seen and treated by general practi-
tioners and other nonpsychiatric specialists in medicine,
as well as their implications and consequences.
However, our ability to successfully capture these con-
cepts in fairly simple variables across large community
surveys is far from perfect. Further, the diagnostic con-
structs used in epidemiological surveys may be well
established in industrially developed,Western societies,
but their reliability and validity has not been adequately
tested in other cultures.
Since the 1980s,with the introduction of the new DSM-III
neurobiological and cognitive model,we have found that,
although the traditional neurotic syndrome may be help-
ful for psychodynamic treatment,this is no longer the case
for behavioral,neurobiological,and pharmacological inter-
ventions.
Thus, the traditional division between International
Classification of Diseases,Ninth Revision
6 (ICD-9) anx-
iety neurosis and phobia should no longer be used.What
used to be anxiety neurosis now includes PD,GAD,and
possibly certain forms of mixed anxiety and depressive
disorders.Phobia is now divided into SP,specific isolated
phobia,and agoraphobia.Some reactionary disorders to
severe stress,like PTSD,should be classified along with
anxiety disorders because the biological and behavioral
mechanisms are very similar.
Aside from the fact that new basic and clinical knowl-
edge no longer matches the traditional grouping of anx-
iety disorders within neurotic disorders, there are also
several practical advantages that make the new diag-
nostic approaches superior.They are easy to use because
the diagnosis is now based on clearly specified descrip-
tive and reliable diagnostic criteria. Because of this
specificity,we have been able to translate the criteria for
each form of anxiety disorder into simple-to-use diag-
nostic questions as part of direct diagnostic instruments
like the World Health Organization (WHO) composite
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Selected abbreviations and acronyms
CIDI composite international diagnostic interview
DIS diagnostic interview schedule
ECA Epidemiological Catchment Area (survey)
GAD generalized anxiety disorder 
GHS The German National Health Interview and
Examination Survey
NCS National Comorbidity Survey
OCD obsessive-compulsive disorder
PD panic disorder
PTSD posttraumatic stress disorder
RBA recurrent brief anxiety
RBD recurrent brief depression
SP social phobiainternational diagnostic interview (CIDI).
6The CIDI has
very high reliability and validity, and can be used even
by nonspecialists without time-consuming diagnosis.
Another advantage is that this new nosography has
brought psychiatry closer to medical science in general.
Mental disorders are no longer vaguely defined expres-
sions of craziness,but are specific,well-defined disorders.
This leads to a better acceptance by patients and their
families. Having a PD is no longer a psychological
defect, a personal weakness, or the result of a neurotic
development.
This very important point has been confirmed by
Wittchen et al
7 in the Munich Study: anxiety disorders
almost never improve spontaneously.In the past,these
disorders were called “minor”and thus they were rarely
specifically treated,unless severe complications occurred.
We have shown that 80% of the people presenting with
such so-called minor disorders did not receive any treat-
ment,with the consequence that they still present the dis-
order 14 years later,with severe implications for every-
day life. Even those few receiving treatment did not
recover completely.It is thus essential to help patients
and their families accept the illness and live with residual
symptoms.
Epidemiology of anxiety disorders: 
general studies
A number of epidemiological studies have shown that
anxiety disorders are highly prevalent and important
causes of functional impairment.Several previous stud-
ies conducted in the USA,UK,and Germany have high-
lighted these problems.
The Epidemiological Catchment Area (ECA) survey
8 is
the largest and most famous psychiatric epidemiological
study carried out in a general population of five American
states (Connecticut,Maryland,Missouri,North Carolina,
and California). Here, we will refine ourselves to dis-
cussing the ECA results on neurotic and anxiety disorders.
The other anxiety disorders were evaluated in only some
of the study areas.The prevalence of PTSD was 1% in
Saint Louis (0.5% in men,1.3% in women;3.5% in crime
victims,20% in Vietnam veterans).GAD has a 12-month
prevalence of 2.3% in Durham, NC (0.8% in men and
2.6% in women) and is not comorbid with another psy-
chiatric disorder in two cases out of three. As in most
other investigations,the ECA study stresses the high rate
of comorbidity of neurotic and anxiety disorders,whether
they are associated with other anxiety disorders or other
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Table I. One-month prevalence data for anxiety disorders as evaluated by the Epidemiological Catchment Area (ECA) study.
7 PD, panic disorder; OCD,
obsessive-compulsive disorder.
1-month prevalence (%)
General prevalence Men Women Total
• All anxiety disorders 4.7 9.7 7.3
• Phobia 3.8 8.40 6.2
• PD 0.3 0.7 0.5
• OCD 1.1 1.5 1.3
Prevalence according to age Men Women Total
• 18-24 years 4.9 10.4 7.7
• 25-44 years 4.7 11.7 8.3
• 45-64 years 5.1 8 6.6
• ≥65 years 3.6 6.8 5.5
Marital status Married Single Separated/divorced Widowed
• All anxiety disorders 6.7 7 11.2 7.6
• Phobia 5.8 5.9 9.3 6.5
• PD 0.5 0.5 1.2 0.5
• OCD 1.1 1.2 2.2 1.4
Socioeconomic status 1 > 2 > 3 > 4
• All anxiety disorders 4.6 6.4 8.5 10.5
• Phobia 3.6 5.7 7.4 8.6
• PD 0.2 0.5 0.5 1.2
• OCD 1 1 1.4 2.1psychiatric disorders.The 1-month prevalence data for
anxiety disorders are presented in Table I.
Another important epidemiological survey,the National
Comorbidity Survey (NCS),was the first study to be car-
ried out in a representative sample of the North
American population;in contrast,the ECA survey only
covered five states.The NCS employed a semistructured
interview approach, enabling investigators to obtain a
diagnosis according to DSM-III-R criteria.
5The subjects
included in the study were aged 15 to 54 years and not
receiving inpatient psychiatric treatment. They were
interviewed by nonmedical interviewers,using a revised
version of CIDI. This revised edition of CIDI was
designed to enable diagnosis according to DSM-III-R
criteria, as well as Diagnostic and Statistical Manual of
Mental Health Disorders,Fourth Edition
9 (DSM-IV) and
the International Statistical Classification of Diseases,
Tenth Revision
10 (ICD-10) criteria. Its aim, which was
complementary to that of the ECA study, was not only
to evaluate prevalence of psychiatric disorders in the
general population, but also to identify certain risk fac-
tors and evaluate psychiatric care needs in inhabitants
throughout the USA.
Approximately half of the subjects who took part suf-
fered from,or had suffered from,at least one psychiatric
event (lifetime prevalence).At the time of the study, a
third of the subjects presented an event or had pre-
sented an event in the previous 12 months (12-month
prevalence).The most common diagnoses were major
depressive events, alcohol dependence, SP, or simple
phobia.More than half of the diagnosed lifetime events
were found in only 14% of the population.This group of
patients had past medical history featuring at least in
three comorbid pathologies, and it is among this group
that the most severe disorders were found.Furthermore,
40% of the subjects who had presented a psychiatric
event in their lifetime had previously received treat-
ment,while only 20% of those who had an event during
the previous 6 months had been treated.
11
The main feature of the NCS is that prevalence rates for
mental disorders in the general population were much
higher that those generally found in most previous stud-
ies,notably ECA study (Table II),in spite of the fact that
the ECA methodology was very similar:
• Use of a semi-structured interview and similar diag-
nostic criteria (revised CIDI and DSM-III-R in the
NCS; and diagnostic interview schedule [DIS] and
DSM-III in the ECA).
• Performed in the general population in North America
(nationwide sample of 8000 subjects aged 15 to 54
years in the NCS; and 20 000 subjects ≥18 years from
five states in the ECA).
• Lifetime and 12-month prevalence in both studies.
• Noninstitutionalized general population in the NCS
and general population weighted by institutionalized
subjects in the ECA.
•Adjusted to correct for nonresponder biases in the
NCS study.
The modest methodological differences between the two
studies would not even have tended to bias results in any
way.The younger NCS study population should have
increased the yearly prevalence of depression, anxiety-
linked disorders, and substance abuse (which are more
common between ages 20 and 50 than after 65 years)
and increased the lifetime prevalence of all types of dis-
orders. However, the equivalent prevalence rates for
mental disorders were only 32% (at least one diagnosis
over a lifetime period) and 20% (at least one diagnosis
over a 12-month period) in the ECA study.
Analysis of the lifetime prevalence rates for each clinical
entity (in decreasing order) provides an explanation.The
difference mainly lies in depressive disorders and addic-
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Table II. Lifetime prevalence of psychiatric disorders in the Epidemiological
Catchment Area (ECA) survey and the National Comorbidity
Survey (NCS).
11 GAD, generalized anxiety disorder; PD, panic dis-
order; OCD, obsessive-compulsive disorder; SP, social phobia.
Lifetime prevalence (%)
NCS ECA
Anxiety disorders
• GAD 5.1 8.5
• Phobic disorder - 14.3
• Phobic disorder (agoraphobia) 5.3 -
• Phobic disorder (SP) 13.3 -
• Phobic disorder (simple phobia) 11.3 -
• PD 3.5 1.6
• OCD - 2.6
Affective disorders
• Major depressive episode 17.1 6.4
• Dysthymic disorder 6.4 3.3
Addiction
• Alcohol abuse and dependence 23.5 11.9
• Drug abuse or dependence 13.8 6.2
Others
• Antisocial personality 3.5 2.6
• Schizophrenic disorder 0.7 1.5tions, whose prevalence could arguably have increased.
The difference in data between the ECA and NCS studies
concerning phobic disorders is comparable to that
observed in data originating between different ECA study
centers,and is probably attributable to semiological data
recording methods.Finally,the prevalence of schizophre-
nia is lower,which could be partly due to a lower preva-
lence of schizophrenia and partly due to the fact that insti-
tutionalized patients were excluded from the NCS study.
On the other hand,Angst and Wicki
12 conducted a study
in Zurich to identify recurrent brief anxiety (RBA) syn-
dromes.The concept of brief and transient psychiatric
pathologies has long been known, but has received an
increasing amount of attention in the past few years.The
terms recurrent brief depression (RBD),RBA,recurrent
brief hypomania, neurasthenia, and insomnia have all
been coined recently. All these syndromes last 1 to 3
days on average,and are highly recurrent (at least once
a month over a whole year).The authors who developed
these concepts have defined them by means of the fol-
lowing diagnostic criteria
12:
•Anxiety (fear of being alone,apprehension of impend-
ing doom,fear of the next day dawning).
•Three of the four GAD symptoms as described in
DSM-III (motor tension,neurovegetative hyperactiv-
ity,apprehension,exacerbated awareness while explor-
ing surroundings).
•Anxious mood for 1 to 13 days, at least once a month
during the previous year.
• Subjective professional impairment of handicap.
The authors
12 noticed that RBA morbidity was often
associated with PDs and RBD, and that many RBA
patients had past familial and personal history of anxiety
and depression.Angst and Wicki therefore suggested that
the association of RBA and RBD could reflect a shared
genetic predisposition for depression and anxiety.
12
The comorbidity rate of RBA with other diagnoses is
such (>75% with depression,>25% with phobias,>16%
with PD, and >6% with GAD) that one can under-
standably challenge the authenticity of this clinical
entity.Furthermore,the symptomatic definition of RBA
does not identify any distinctive characteristic from
those of GAD,aside from duration.
These concepts can be questioned in the same way that
one can challenge the existence of subsyndromic states.
These states are related to entities defined by classical
criteria systems (DSM-III,DSM-IV,or ICD-10),but dif-
fer only because they consist of n-1 or n-2 symptoms.In
the case of brief recurrent syndromes, the duration of
psychological suffering is significantly shortened.
There are still few studies in France concerning the
prevalence of anxiety and somatoform disorders among
outpatients.Lepine et al
13 examined a general psychiatric
outpatients sample (n=1271),gathered through a cross-
national French survey.Anxiety and somatoform syn-
dromes were assessed according to DSM-III and DSM-
III-R criteria.Lifetime and 1-month prevalence rates in
this population were reported and a high level of comor-
bidity between anxiety syndromes was observed.
Another epidemiological survey was conducted by
Lepine and Lellouch
14 in the general population in an
suburban development of the greater Paris area, and
evaluated the prevalence of risk factor for anxiety and
depressive disorders, based on the DSM-III-R criteria,
using standardized interviews (DIS and CIDI).
Data were obtained for 1787 subjects randomly chosen
from a telephone directory.One problem was the high rate
of refusal to participate (35%). Furthermore, the study
area greatly influenced the sociodemographic character-
istics of the study population:young age (average:36 years
in women and 38 years in men),mostly married,working
primarily in the tertiary sector,with 71% of the women
aged 20 to 64 years being part of the active work force.
The anxiety and depression disorder prevalence data
found in this study are consistent with those found in the
international literature (Figure 1).They are,however,to
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Figure 1. Prevalence of Diagnostic and Statistical Manual of Mental
Disorders, Revised Third Edition (DSM-III-R) disorders in an out-
patient sample (n=1271). NA, not available.
Adapted from reference 14: Lepine JP, Lellouch J. Etude épidémiologique
des troubles dépressifs et anxieux dans une population générale. Ann
Med Psychol. 1993;151:618-623.
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complaintsbe compared with the data found in the upper limit of
this bracket. As was the case in the NCS, these data
underline the high rate of comorbidity between anxiety
and depressive disorders. Furthermore, in this study of
French population,Lepine and Lellouch
14 find the same
cohort effect as that found in other Western countries:
an increase in the prevalence of depression in cohorts of
subjects born after the end of the Second World War.
The epidemiology of anxiety disorders:
focused studies
Generalized anxiety disorder
Diagnosis
The DSM-III criteria for GAD require the presence of
unrealistic or excessive anxiety and worry,accompanied
by symptoms from three of the following categories:motor
tension,autonomic hyperactivity,vigilance and scanning,
and apprehensive expectation.The anxious mood must
continue for at least a month, and the diagnosis is not
made if phobia, PD, or OCD is present, or if the distur-
bance is due to another physical or mental disorder,such
as hyperthyroidism,major depression,or schizophrenia.
By this definition,GAD is treated primarily as a residual
category after exclusion of the other major anxiety disor-
ders.DSM-III-R narrowed the definition further by requir-
ing a minimum of six symptoms and a duration of 6
months.DSM-IV required only three symptoms from a list
of six,but added the requirement that the anxiety causes
clinically significant distress or functional impairment.
Symptoms
• Pervasive anxiety and worry persisting for at least 6
month (to a degree out of proportion to actual likelihood
of effect of the event), motor tension, hyperarousal;
many patients may report being anxious all their lives.
• Significant impairment of daily life: sleep problems,
headaches,the “jitters,”nausea,tense muscles,and trem-
bling or hot flashes are common;fatigue and difficulty
concentrating may cause difficulties at work or home.
Prevalence
The literature reviewed here is consistent in showing that
GAD is common mental disorder that typically has an
early age of onset,a chronic course,and a high degree of
comorbidity with other anxiety and mood disorders.
Comorbidity GAD is often temporally primary,especially
in relation to mood disorders, and is associated with an
increased risk for the subsequent onset and severity of sec-
ondary disorders.The weight of evidence reviewed here
argues against the view expressed by early commentators
that GAD is better conceptualized as a prodrome,resid-
ual,or severity marker of other disorders than as an inde-
pendent disorder.Focused studies of comorbidity between
GAD and major depression,in which comorbidity is high,
reached the same conclusion.
15The crucial evidence for
this conclusion includes the following:
• Contrary the findings of clinical studies, GAD in the
community does not have a higher comorbidity than
most other anxiety or mood disorders.
•The symptoms of GAD form an empirical cluster dis-
tinct from the symptoms of major depression in stud-
ies of symptom profiles.
• Family studies show distinct aggregation of GAD and
major depression.
•Twin studies show that the environmental determi-
nants of GAD are different from those of major
depression.
•The sociodemographic predictors of GAD in epi-
demiological studies are different from those of major
depression.
16
•The clinical course of GAD is less consistently related
to comorbidity than the course of other anxiety and
mood disorders.
17
•The impairments associated with GAD are equivalent
to—or greater than—those associated with other severely
impairing chronic physical and mental disorders.
18-20
These findings show that the status of GAD as an inde-
pendent disorder is at least as strongly supported by
available evidence as other anxiety or mood disorders.
21
Despite the fact that there have been many changes in the
diagnostic criteria for GAD over recent years,reported
lifetime prevalence estimates in the general population
(Table III) are remarkably stable, especially compared
with the considerable variance observed with other psy-
chiatric disorders,such as depression and PD,over a simi-
lar age span.On the basis of more recent studies,the most
likely lifetime prevalence rate for GAD in the general
population is 5% using DSM criteria and may be slightly
higher when using the broader ICD-10 criteria (6.5%)
(Table III).
13,22-27 Current and 12-month prevalence rates for
GAD are reported in Tables IV
22,25,26,28-32 and V,
22,26,27,33-37
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the definition of current prevalence (for current prevalence
[also known as point prevalence],the exposure and out-
come are both determined at the same point or cross-sec-
tion in time,using a cross-sectional study) and are subject
to more variation than lifetime prevalence estimates.The
most likely current prevalence rate in the general popula-
tion seems to be in the range of 2% to 3% (DSM criteria).
The NCS,
11 which was performed in a representative sam-
ple of the US general population,is the largest study to
report epidemiological findings for GAD to date.
26 Using
CIDI/DSM-III-R criteria in more than 8000 respondents,
a lifetime prevalence estimate of 5.1% (3.6% in men and
6.61% in women) and a 12-month prevalence rate of 3.1%
(2.0% in men and 4.3% in women) were reported.The
lifetime prevalence estimate is in relatively good agree-
ment with the findings of several other large epidemio-
logical studies that have been conducted throughout the
world in recent years.The 12-month prevalence rate found
by the NCS should be regarded with caution, however,
since the CIDI is designed to gather lifetime prevalence
rates and did not assess the presence of all of the disorder’s
criteria in the preceding 12 months,and thus might include
a high proportion of people with lifetime GAD who have
only had some significant signs of the disorder during the
previous month.The 12-month prevalence estimates of
threshold GAD were recently found to be lower in the
German National Health Interview and Examination
Survey (GHS),Mental Health Supplement.
37This study
used the slightly stricter DSM-IV criteria (which use the
additional criteria of difficulty controlling worry and a
restricted range of associated symptoms),which increase
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Table III. Lifetime prevalence of generalized anxiety disorder (GAD) in general population surveys. ECA, Epidemiological Catchment Area; NCS, National
Comorbidity Survey; WHO, World Health Organization; DSM, Diagnostic and Statistical Manual of Mental Disorders.
Site Diagnostic criteria Lifetime prevalence (%) Source
ECA, Durham, NC DSM-III 6.6 Blazer et al,
22 1991
ECA, Saint Louis, Mo DSM-III 6.6 Blazer et al,
22 1991
ECA, Los Angeles, Calif DSM-III 4.1 Blazer et al,
22 1991
Iceland DSM-III 21.7 Stefanson et al,
23 1991
Shatin, Hong Kong DSM-III 7.8 (men) Chen et al,
24 1993
11.1 (women)
Florence, Italy DSM-III-R 5.4 Faravelli et al,
25 1989
NCS, USA DSM-III-R 5.1 Wittchen et al,
26 1994
Munich, Germany DSM-IV 0.8  Wittchen et al,
27 1998
(adolescents; young adults)
Savigny, France DSM-III-R 5.4 (men) Lepine et al,
13 1989
13.4 (women)
Table IV. Current prevalence of generalized anxiety disorder (GAD) in general population surveys. ECA, Epidemiological Catchment Area; NCS, National
Comorbidity Survey; WHO, World Health Organization; RDC, research diagnostic criteria; DSM, Diagnostic and Statistical Manual of Mental
Disorders; ICD, International Classification of Diseases.
Site Diagnostic criteria Current prevalence (%) Source
ECA, USA RDC 2.5 Weissman et al,
28 1978
ECA, Durham, NC DSM-III 1.2 Blazer et al,
22 1991
ECA, Saint Louis, Mo DSM-III 1.3 Blazer et al,
22 1991
ECA, Los Angeles, Calif DSM-III 1.4 Blazer et al,
22 1991
Florence, Italy DSM-III-R 2.8 Faravelli et al,
25 1989
NCS, USA DSM-III-R 1.6 Wittchen et al,
26 1994
Spain DSM-III-R 0 (18 years old) Canal et al,
29 1997
Great Britain ICD-10 6.4 Jenkins et al,
30 1997
South Africa DSM-IV 3.7 Bhagwanjee et al,
31 1998
WHO ICD-10 5.7 (1.1-25.8) (men) Gater et al,
32 1998
9.2 (0.5-14.1) (women)the duration criterion from 1 to 6 months compared with
DSM-III-R, to examine GAD and other disorders in a
representative sample of the German population (over
7200 adults). Using a 12-month version of the Munich
CIDI,
38 the 12-month prevalence rate for GAD (meeting
all DSM-IV criteria) was found to be 1.5% (1.0% in men
and 2.1% in women).
When, however, lifetime GAD cases with still-existing,
12-month subthreshold GAD syndromes are counted as
well—as was the case in the NCS study—an almost iden-
tical 12-month rate of 3.6% (2.4% in men and 4.9% in
women) was confirmed. In addition, the disorder was
found to be significantly more frequent in women than
in men (odds ratio [OR] =2.1;P<0.05).The investigators
also determined prevalence rates for subthreshold
expressions of GAD by using different time criteria for
duration, such as worrying for at least 1 month (7.8%)
or worrying for at least 3 months (4.1%),and concluded
that long periods of anxious worrying associated with
subthreshold GAD symptoms are much more wide-
spread in the community than threshold GAD.
When prevalence data from the NCS and GHS are exam-
ined by age,it is clear that for both lifetime and 12-month
prevalence rates,the lowest rates for GAD occur in the
younger age groups and the highest rates are found in the
older study participants.
26,37 In the GHS,the likelihood of
receiving a diagnosis of GAD increased significantly with
age (18-34 versus 35-65 years;OR=1.0;P<0.05) when con-
trolling for differences in gender,with point prevalence
rates up to 4.4% in women aged 45 or older.These find-
ings are consistent with the lower prevalence rates for
GAD recorded in studies of adolescents and young adults.
Despite differences in diagnostic criteria,the ECA,
22 the
NCS,
26 and the Savigny study
13 rates of GAD were quite
similar.Lifetime prevalence varied considerably more in
the Iceland and Hong Kong studies
24 from 7.8% in Hong
Kong (women) to 21.7% in Iceland.
25The Florence study
26
provides an interesting example of the effects of requiring
the longer 6-month duration of DSM-III-R.For DSM-III,
the lifetime prevalence rate was 5.4%,while the narrower
DSM-III-R definition resulted in the lower rate of 3.9%.
Another clinical and epidemiological study of GAD in
general practice
39 indicates that,among a sample of 1117
patients,15.4% were given a GAD diagnosis (DSM-III);
there were predominantly women and aged between 35
and 50 years.On the other hand,GAD (and PD) is unique
among anxiety disorders in that patients commonly pre-
sent to primary care physicians for treatment.
40
An international WHO study used ICD-10 criteria and
the CIDI to assess GAD and estimated the current
prevalence of GAD to be approximately 8% of all pri-
mary care attendees.
41 A more recent reanalysis con-
firmed these results by using more sophisticated analy-
ses, finding a mean current prevalence rate of 7.9%.
40
This study also found a wide range of prevalence rates
across the participating countries, for example, 3.8% in
Italy and 14.8% in Greece,possibly owing to differences
in the way that countries and regions organize the pro-
vision of primary care services.It is noteworthy that this
study suggests that the point prevalence rate of GAD is
considerably higher in primary care than that reported
in the general population,suggesting that GAD patients
are high utilizers of primary care resources.
42 This is in
contrast to social anxiety disorder and most other anxi-
ety disorders,for which the point prevalence rates in the
general population are much higher than in primary
care,and subjects are unlikely to present to their family
doctor owing to the nature of the condition.
43,44
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Table V. Twelve-month prevalence of generalized anxiety disorder (GAD) in general population surveys. ECA, Epidemiological Catchment Area; NCS,
National Comorbidity Survey; GHS, German National Health Interview and Examination Survey; WHO, World Health Organization; DSM,
Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases.
Site Diagnostic criteria 12-month prevalence (%) Source
Zurich, Switzerland DSM-III 3.8 Angst et al,
33 1982
ECA, Saint Louis, Mo DSM-III 2.9 Blazer et al,
22 1991
ECA, Durham, NC DSM-III 3.6 Blazer et al,
22 1991
ECA, Los Angeles, Calif DSM-III 2.0 Blazer et al,
22 1991
NCS, USA DSM-III-R 3.1 Wittchen et al,
26 1994
Ontario, Canada DSM-III-R 1.1 Offord et al,
35 1996
Dunedin, New Zealand DSM-III-R 1.8 (18 years old) Feehan et al,
36 1994
Munich, Germany DSM-IV 0.5 (adolescents, young adults) Wittchen et al,
27 1998
GHS, Germany DSM-IV 1.5 Carter et al,
37 2001Panic disorder
Diagnosis
The key feature of PD in DSM-III is the occurrence of
three or more panic attacks within a 3-week period.
These attacks must not have been precipitated simply by
exposure to a feared situation, must not be due to a
physical disorder, and must be accompanied by at least
four of the following symptoms: dyspnea, palpitations,
chest pain, smothering or choking, dizziness, feelings of
unreality, paresthesias, hot and cold flashes, sweating,
faintness, trembling, or shaking. In DSM-III-R, the def-
inition was revised to require four attacks in 4 weeks,or
one or more attacks followed by a persistent fear of hav-
ing another attack, and the list of potential symptoms
was revised to include nausea or abdominal distress and
to exclude depersonalization or derealization.
More importantly, DSM-III-R changed the diagnostic
hierarchy such that PD could be diagnosed as a primary
disorder with or without agoraphobia,and also dropped
the category of agoraphobia with panic attacks. This
change emphasized identifying PD as a discrete entity,
and reflected the clinical experience that panic attacks
tended to occur prior to the development of agorapho-
bia, which was increasingly viewed as a phobic avoid-
ance response to the frightening experience of sponta-
neous panic attacks, near panic experiences, or limited
symptom attacks.
45
DSM-IV criteria require recurrent unexpected panic
attacks and persistent concern about having further
attacks,worry about the implications of the attacks,or a
significant change in behavior due to the attacks.
Epidemiological data using these criteria are not available.
Symptoms (with or without agoraphobia)
• Unexpected,recurrent,abrupt episode of intense fear
or discomfort (ie, panic attacks) that peak within 10
min and may involve multiple systems.
• Feelings of unreality,detachment from self,and intense
fear of losing control, choking, going crazy, having a
heart attack,or dying during a panic attack.
• Recurrent and unexpected panic attacks and, for at
least 1 month after an episode,concerns about the con-
sequences of a prior attack or having another attack
(ie,PD).
• Symptoms of agoraphobia may be present:fear of get-
ting into situations or going to places where a panic
attack may occur and there is no escape or availability
of help.
Prevalence
Table VI
7,8,11,14,25,46-52 shows prevalence rates for PD from a
cross-national collaborative study in 10 countries,using
DIS and DSM-III criteria.These 10 community studies
included over 40 000 subjects, who were analyzed with
appropriate standardization for age and sex differences
among subjects from different countries. For compari-
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Table VI. Lifetime prevalence rates for panic disorder (PD) in several community studies (age 18 to 64 years). ECA, Epidemiologic Catchment Area
survey; NCS, National Comorbidity Survey.
Site n 12-month prevalence (%) Lifetime prevalence (%) Female/male ratio
Total Men Women
ECA, USA 18 572 1.0 1.7 1.0 2.3 2.3
NCS, USA 8098 2.2 3.5 1.9 5.1 2.7
Edmonton, Canada 3258 0.9 1.4 0.9 1.9 2.1
Puerto Rico 1513 1.1 1.7 1.4 1.8 1.3
Savigny, France 1787 0.9 2.2 1.3 3.0 2.3
Munich, Germany 481 1.7 2.6 1.4 3.8 2.7
Florence, Italy 1110 1.3 2.9 1.2 3.9 3.2
Beirut, Lebanon 223 2.1 2.1 1.1 3.1 2.8
Taipei, Taiwan 11 004 0.2 0.4 0.2 0.6 3.0
Seoul, Korea 5075 1.6 1.7 0.5 2.9 5.8
New Zealand 1498 1.3 2.1 0.7 3.3 4.7
Iceland 862 - 2.1 3.1 1.1 -
France (National Survey) 15 871 1.2 - - - -son purposes,Table VI also includes data from the NCS,
11
a representative sample of 8098 persons living in the 48
coterminous states in the USA and conducted between
1990 and 1992,using the University of Michigan version
of the Composite International Diagnostic Interview
(UM-CIDI) and DSM-III-R criteria.The annual rate of
DSM-III PD ranged from 0.2% in Taiwan to 2.1% in
Beirut, Lebanon.The NCS reported an annual preva-
lence of 2.2% for DSM-III-R PD.
53,54
Lifetime prevalence rates of DSM-III PD showed excel-
lent agreement,with the prevalence varying from 1.4% in
Edmonton,Canada,to 2.9% in Florence,Italy.The excep-
tion to this narrow range was Taiwan,where DSM-III PD
had a lifetime prevalence of 0.4%.The lower rates of PD
in Taiwan are consistent with lower Taiwanese rates for
most other disorders studied.The reasons for these lower
rates are not clear.The only study that reported on life-
time DSM-III-R PD was the NCS,which found a rate of
3.5%,somewhat higher than the lifetime prevalence rates
based on DSM-III.The higher annual and lifetime rates
reported in the NCS may be caused by a period effect,
with increasing rates between the ECA of the early 1980s
and the NCS of the early 1990s.Other contributors to the
higher rate in the NCS may include the broadening of the
concept of PD in DSM-III-R compared with DSM-III
and the differences in memory probes used in the NCS
interview (the UM-CIDI) compared with the cross-
national study (the DIS interview).
28
The age at onset of PD is usually in the early to middle
twenties,with a later onset in West Germany (Munich)
7
and Korea
50 (age 35.5 and 32.1,respectively).In the NCS
data, a bimodal distribution of age of onset was
reported, with an early mode for PD in the 15- to 24-
year age range for both men and women, and a later
mode in the 45- to 54-year age range.
Most of the evidence regarding clinical course comes
from clinical studies, which suggest that PD has a fluc-
tuating course with varying levels of severity over time.
Two longitudinal epidemiological studies, the Munich
Follow-up Study (MFS)
7 and the Zurich study, showed
that a substantial proportion of persons with PD go on
to develop comorbid panic and depression and that
these cases are associated with a less favorable course
and outcome. Longitudinally, cases with both disorders
have very high treatment rates and a high rate of suicide
attempt.
At every cross-national site and in the NCS, PD was
associated strongly with an increased risk for major
depression and agoraphobia.The ORs for comorbidity
of lifetime PD with agoraphobia ranged from OR=7.5
in the ECA to OR=21.4 in Puerto Rico, with the NCS
reporting OR=10.6 (Table VI).
8,11,14,46,47,49-51 On the basis of
lifetime prevalence rates,the OR for comorbidity of PD
with major depression ranged from OR=3.8 in Savigny,
France,to OR=20.1 in Edmonton,Canada,with OR=5.7
reported in the NCS (Table VII).
Finally, comparing lifetime prevalence rates, all of the
studies reporting on PD showed higher rates for women
than for men.In an analysis of the data,Eaton and col-
leagues
45 found uniformly higher rates of panic attacks
and PD for women over men within every age group.Of
interest,Keyl and Eaton
55 analyzed incidence rates from
the ECA study and found a twofold increased risk of inci-
dent PD in women over men.
56This finding is analogous
to the increased incidence and prevalence rates for major
depression in women versus men.It suggests that for both
PD and major depression, the higher rates in women
reflect a true increase in the risk for new-onset PD and
major depression,rather than a greater tendency to seek
treatment or have longer episodes of illness.
Agoraphobia
Diagnosis
DSM-III agoraphobia is defined as a fear and avoidance
of being in places or situations from which escape might
be difficult or in which help might not be available in the
event of sudden incapacitation.As a result of such fears,
the agoraphobic person avoids travel outside the home or
requires a companion when away from home.Moderate
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Table VII. Comorbidity of panic disorder (PD) with lifetime agoraphobia
and major depression. ECA, Epidemiological Catchment Area
survey; NCS, National Comorbidity Survey; OR, odds ratio; CI,
confidence interval.
Site PD with agoraphobia Major depression
OR (95% Cl) OR (95% Cl)
ECA, USA 7.5 (5.5-10.1) 8.7 (6.4-11.7)
NCS, USA 10.6 (7.3-15.5) 5.7 (4.0-8.1)
Edmonton, Canada 15.1 (7.6-29.9) 20.1 (10.4-38.8)
Puerto Rico 21.4 (9.2-50.2) 15.3 (6.4-36.6)
Savigny, France 12.7 (6.8-24.0) 3.8 (2.1-7.1)
Taipei, Taiwan 17.2 (8.0-37.2) 19.6 (9.1-42.1)
Seoul, Korea 17.2 (10.6-27.8) 13.2 (8.0-21.6)
New Zealand 9.4 (4.2-21.2) 4.6 (2.2-9.4)cases may cause some constriction in lifestyle, while
severe cases of agoraphobia may result in the person
being completely housebound or unable to leave home
unaccompanied.
As outlined in the PD section above,DSM-III-R revised
the diagnosis of agoraphobia to a condition accompa-
nying PD (PD with agoraphobia) or panic-like symp-
toms.Although the diagnosis of agoraphobia without
history of PD was retained, this category emphasized
avoidance behavior as a response to the sudden devel-
opment of anxiety or somatic symptoms. DSM-IV has
further emphasized that the agoraphobic avoidance
behavior occurs specifically in response to the fear of
developing panic-like symptoms.
Prevalence
Lifetime prevalence rates of agoraphobia have been
reported in a number of studies. If one considers only
the studies carried out in primarily English-speaking
countries,the lifetime prevalence rates vary over a nar-
row range from 2.9% in Edmonton,Canada,to 6.7% in
the NCS.
11 Despite the changes in the diagnostic defini-
tion between DSM-III and DSM-III-R,the lifetime rates
from the ECA and NCS studies showed remarkable
consistency (5.6% and 6%-7%, respectively).As with
other disorders,Taiwan reported a lower rate of agora-
phobia (1.3%).
On the other hand,as shown in Table VIII,
8,11,14,46,47,49-51 the
Cross-national Collaborative Study and the NCS iden-
tified PD as a uniformly powerful risk factor for agora-
phobia across a wide array of study sites.Nonetheless,in
DSM-III, agoraphobia was considered to be a separate
phobic disorder that may or may not be accompanied by
panic attacks. Largely due to the influence of Klein’s
hypothesis that agoraphobia is a conditioned avoidance
response to the aversive stimulus of spontaneous panic
attacks,the diagnostic view of agoraphobia changed con-
siderably in DSM-III-R, in which PD is viewed as pri-
mary,with or without secondary development of agora-
phobia. An important factor in this change was the
observation by Klein
3 and others that,in clinical settings,
agoraphobia rarely occurs without preceding sponta-
neous panic attacks or limited symptom attacks.
However, Marks and other investigators
57 have ques-
tioned the temporal precedence and causal role of panic
attacks in the development of agoraphobia.
The large differences between clinic and community
studies in estimates of the relative prevalence of agora-
phobia with and without panic attacks contribute to the
controversy.Population-based surveys have identified a
substantial number of subjects with agoraphobia and no
history of panic attacks. For the most part, subjects in
these surveys were interviewed by laypersons using the
DIS. In contrast, clinic-based studies, using less struc-
tured interviews administered by clinicians, almost
invariably found much lower rates of agoraphobia with-
out panic.
Several explanations for this discrepancy have been sug-
gested. One is that treated samples of persons with any
illness have higher rates of comorbidity than untreated
samples.An alternative explanation is that population
studies may have overestimated the rate of agoraphobia
without PD.
In a reanalysis of the ECA data on agoraphobia without
panic,22 community cases of agoraphobia without panic
were clinically reappraised and only a single case of prob-
able agoraphobia without panic was found.
28 The diag-
nostic reappraisal found that 19 (87%) of the cases had
simple or SPs rather than agoraphobia, or no DSM-III
phobia at all.The reappraisal also identified 6 cases of PD,
panic attacks,or limited symptom attacks that had been
missed by the DIS interview.The authors concluded that
community studies using the DIS may have overesti-
mated the prevalence of agoraphobia without panic
attacks in the community.
An initial analysis of the NCS data found that only
about one-third of NCS agoraphobics reported a history
of panic attack.More detailed analyses of the NCS data
are under way to determine whether agoraphobia with-
out panic is in fact as common as the initial analyses
suggest.
The epidemiology of anxiety disorders - Martin  Dialogues in Clinical Neuroscience - Vol 5 . No.3 . 2003
291
Table VIII. Comorbidity of panic disorder (PD) with lifetime agoraphobia.
ECA, Epidemiological Catchment Area survey; NCS, National
Comorbidity Survey.
Site Lifetime prevalence of agoraphobia (%)
With panic Without panic
ECA, USA 33.8 5.5
NCS, USA 38.8 5.1
Edmonton, Canada 31.8 2.7
Puerto Rico 58.2 6.0
Savigny, France 48.9 6.5
Taipei, Taiwan 22.5 1.4
Seoul, Korea 34.7 2.1
New Zealand 29.5 3.4Social phobia
Diagnosis
SP is a common disorder associated with significant psy-
chosocial impairment, representing a substantial public
health problem, largely determined by high prevalence
and lifelong chronicity. SP starts in early childhood or
adolescence, and is often comorbid with depression,
other anxiety disorders,alcohol and substance abuse,or
eating disorders.
58 This cascade of comorbidity, usually
secondary to SP,increases the disability associated with
the condition.
The central feature of DSM-III SP is a persistent, irra-
tional fear accompanied by a compelling desire to avoid
situations in which a person may act in a humiliating or
embarrassing way while under the scrutiny of others.
DSM-III-R allowed for the phobic situation to be
avoided or endured with intense anxiety,and added the
requirement that the avoidant behavior interferes with
occupational or social functioning or that there is
marked distress about having the fear. DSM-IV adds
that the person recognizes the fear as excessive or unrea-
sonable.
59
Common SPs involve fears of speaking or eating in pub-
lic,urinating in public lavatories,writing in front of oth-
ers,or saying foolish things in social situations.
Symptoms (social specific)
• Unreasonable or excessive fear of social situations (eg,
being embarrassed during a performance), specific
objects (eg, cats, clowns, spiders), or situations (eg,
being in tunnels or darkness).
•Avoidance of feared situation or object,or endurance
of it with intense anxiety.
• Significant distress or social and occupational dys-
function.
Prevalence
Table IX
8,11,46,47,50 shows the lifetime prevalence of DSM-
III SP from a cross-national study reporting from the
US, Canada, Puerto Rico, and Korea; for comparison,
the lifetime prevalence of DSM-III-R SP is also
included.Lifetime prevalence rates of DSM-III SP var-
ied somewhat,with a low of 0.5% in Korea and a high of
2.6% in the US.It is not clear whether these contrasting
rates reflect true cross-cultural differences or differences
in methodology or translation of the DIS.
The lifetime prevalence of DSM-III-R SP from the NCS
was considerably higher (13.3%) than in any of the
DIS/DSM-III studies.Magee and colleagues
60 attributed
the higher prevalence to differences between the DIS and
UM-CIDI.The UM-CIDI uses a stem question based on
the broader DSM-III-R criteria allowing either avoidance
of a feared situation or endurance with intense anxiety.It
also asks about six specific SP fears (versus three in the
DIS),including the high prevalence fears of using a pub-
lic toilet,writing in front of others,or talking to people and
sounding foolish or having nothing to say.
In the Cross-national Collaborative Study data reported
in Table IX,the mean age at onset of first phobia ranged
from the mid-teens to early twenties.The NCS reported a
median age at onset for SP of 16 years.SP appears to be a
chronic disorder,which can disrupt academic achievement,
and impair social development and job performance.
The vast majority of SPs occurred in persons who reported
at least one other psychiatric disorder.Both the NCS and
the cross-national studies reported that persons with SP
usually suffered a first onset of phobia prior to the onset
of other psychiatric disorders.
61The course of SP is often
marked by development of other comorbid psychiatric dis-
orders.As in other instances of comorbid disorders,these
cases may be associated with greater degrees of functional
impairment and treatment seeking
62 and suicide.
63
Obsessive-compulsive disorder
Diagnosis
DSM-III diagnostic criteria for OCD require the presence
of obsessions or compulsions that are sources of significant
distress or impairment and are not due to another mental
disorder.
64 DSM-III-R requires that the obsessions or com-
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Table IX. Lifetime prevalence rates for social phobia (SP) disorder in sev-
eral community studies. ECA, Epidemiological Catchment Area
survey; NCS, National Comorbidity Survey.
Site Lifetime prevalence (%)
Total Women Men
ECA, USA 2.6 2.1 3.1
NCS, USA 13.3 11.1 13.3
Edmonton, Canada 1.7 1.3 2.1
Puerto Rico 1.0 0.8 1.1
Seoul, Korea 0.5 0.1 1.0pulsions cause marked distress,consume more than 1 hour
a day,or significantly interfere with the person’s normal
routine or occupational or social functioning.
65 DSM-IV
adds the requirement that the person has recognized that
the obsessions or compulsions are excessive or unreason-
able. Obsessions are defined as recurrent, persistent
thoughts,images,or impulses that are experienced as intru-
sive and inappropriate.Compulsions are repetitive behav-
iors (eg,checking locked doors or gas jets,hand washing)
or mental acts (eg,counting,repeating words) that the per-
son feels driven to perform in response to an obsession or
according to rigid rules.
66
Symptoms
• Intrusive and recurrent thoughts,impulses and images
that cause distress and impairment (obsessions); per-
formance of ritualized behaviors (compulsions) to
relieve anxiety obsessions or compulsions that inter-
fere with daily life and usually take up at least 1 hour
of the patient’s day.
• Realization that compulsive behaviors are senseless.
• Common obsessions involve germs and disease
(becoming sick or making others sick), of being
harmed or harming others; cleanliness, neatness, sym-
metry,disturbing sexual images.
• Common compulsions include repeated hand washing,
tooth brushing, avoiding touching “contaminated”
objects,counting,and checking.
Prevalence
Table X
7,8,46,47,49-51 shows lifetime prevalence rates of DSM-
III OCD from the Cross-national Collaborative Group.
Lifetime prevalence of OCD varied from 0.7% in
Taiwan to 2.5% in Puerto Rico.The studies in English-
language sites showed excellent agreement,with lifetime
prevalence of 2.2% to 2.3% in the USA, Canada, and
New Zealand.Most remarkable about these rates is that
they contradict the previous traditional view of OCD 
as a rare disorder on the basis of published clinical
reports.
67
On the other hand, in the Cross-national Collaborative
Group data,the mean age at onset of OCD was the mid-
twenties to early thirties. The youngest mean age at
onset was reported in Edmonton, Canada (21.9 years)
and the oldest in Puerto Rico (35.5 years).
One epidemiological study has investigated the preva-
lence of OCD among adolescents and provided follow-
up data regarding the course of OCD symptoms.Valleni-
Basile et al
68 surveyed a community sample of 3283 ado-
lescents in the southeastern USA and found a 3%
prevalence of OCD.They also identified a group of ado-
lescents who had symptoms of OCD, but were not con-
sidered impaired.The prevalence of subclinical OCD,by
this definition, was 19%. In a separate study,Valleni-
Basile et al
68 found that the 1-year incidence rate of
OCD in this population was 0.7%. Interestingly, an ini-
tial diagnosis of subclinical OCD was not significantly
predictive of a diagnosis of OCD at 1-year follow-up.
The authors concluded that an initial diagnosis of sub-
clinical OCD was not a precursor to the development of
clinical OCD with impairment of functioning.
In the ECA study,prevalence rates of OCD were higher
among women than men. However, when gender com-
parisons were controlled for marital status,employment
status, job status, ethnicity, and age, there were no
remaining differences in prevalence rates for women
and men. In the Cross-national Collaborative Study,
rates were generally higher in women,except in Munich,
where the rates were higher among men.
At least one prospective epidemiological study has sug-
gested candidate risk factors for OCD. Crum and
Anthony used data from the ECA study to estimate the
degree to which the risk of OCD might be elevated
among adults actively using cocaine.
69 Using 1-year
prospective follow-up data,they identified 105 incident
cases of OCD among 13 306 at-risk study participants.
Subjects actively using cocaine were at substantially
increased risk for OCD.
In the Cross-national Collaborative Study,persons with
OCD were found to have a substantially greater risk of
having comorbid major depression or another anxiety
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Table X. Lifetime prevalence rates for obsessive-compulsive disorder (OCD)
in several community studies. ECA, Epidemiological Catchment
Area survey.
Site Lifetime prevalence (%) Female/male
Total Women Men ratio
ECA, USA 2.3 1.7 2.8 1.6
Edmonton, Canada 2.3 2.0 2.7 1.3
Puerto Rico 2.5 2.3 2.7 1.2
Munich, Germany 2.1 2.5 1.9 0.8
Taipei, Taiwan 0.7 0.5 0.9 1.8
Seoul, Korea 1.9 1.7 2.0 1.2
New Zealand 2.2 0.9 3.4 3.8disorder compared with persons without OCD across all
sites,even though the comorbidity rates and the magni-
tude of the risk varied by site.The proportion of persons
with OCD and any anxiety disorder was higher than the
proportion with major depression at all sites.
70
Posttraumatic stress disorder
Diagnosis
PTSD is defined in DSM-III as a constellation of symp-
toms in response to a stressor,including reexperiencing
a traumatic event, a numbing of responsiveness, and
symptoms of an increased level of arousal.
71,72
In DSM-III-R,the symptoms are required to persist for at
least 1 month and the criteria are broadened by adding
intense psychological distress in response to events that
symbolize or resemble an aspect of the trauma and avoid-
ance of stimuli associated with the event.
73 In DSM-IV,the
requirement for functional impairment or clinically sig-
nificant distress is added.
74
Symptoms (acute 2-4 weeks;chronic >4 weeks)
• Reexperiencing a traumatic event in recollections,
dreams,flashbacks.
•Avoidance of stimuli associated with the event.
• Sleep disturbances,hypervigilance.
Prevalence
Until recently, accurate information on the prevalence
of PTSD was not available.Earlier studies on the effects
of traumatic experiences tended to focus on groups who
had been exposed to a common trauma,such as Vietnam
War veterans or survivors of natural disasters.However,
in the last decade,several surveys have gathered general
population data, which have enhanced our knowledge
of the extent and seriousness of the impact of PTSD on
the community.
Table XI
75-78 presents lifetime prevalence rates of PTSD
from five surveys conducted in the USA using DSM-III
or DSM-III-R diagnostic criteria.
79The DSM-III studies,
which were both part of the ECA and used the DIS as the
diagnostic instrument, found a low lifetime prevalence
rate of 1.0 to 1.3 per 100 subjects.More importantly,these
and other studies using DSM-III generated reliable,sys-
tematic data on the nature of the response to various trau-
mas,including criminal victimization,sexual assault,nat-
ural disaster, and combat.
80 This empirical information
contributed to the revisions of the diagnostic criteria in
DSM-III-R. The early studies also resulted in a better
understanding of the effects of trauma and improvements
in the assessment of populations for the presence of trau-
matic life events and the symptoms of PTSD.
Later studies using DSM-III-R criteria found a lifetime
prevalence of PTSD ranging from 10.4 to 12.3 per 100
women and 5.0 to 6.0 per 100 men.The latter studies
seem to confirm that PTSD is a highly prevalent disor-
der,and also provide evidence that the traumatic events
causing PTSD are experienced quite commonly in the
community.In the NCS,61% of men and 51% of women
reported at least one traumatic event.
81 Men were more
likely than women to experience physical attacks, com-
bat, being threatened with a weapon, held captive, or
kidnapped.Women were more likely to experience rape,
sexual molestation, childhood parental neglect, and
childhood physical abuse.
However, epidemiological studies of PTSD have often
assessed at-risk groups of survivors of specific type of
trauma,such as veterans of armed conflicts,displaced per-
sons and refugees,and victims of range of criminal acts,
including sexual assaults,
82 terrorist attacks,
83 and torture.
84
On the other hand,the epidemiological data suggest that
the relationship between trauma exposure and develop-
ment of PTSD is complex.Men and women differ in the
types of traumas to which they are likely to be exposed,
and they differ in their liability to develop PTSD once
exposed.The lifetime prevalence of PTSD is significantly
higher in women than in men.Women are more likely
than men to be exposed to “high-impact” traumas, or
traumas that are associated with a high probability of
developing PTSD. Furthermore, once exposed to trau-
matic events,a higher proportion of women than men go
on to develop PTSD. The vast majority of men and
women who met criteria for DSM-III-R PTSD also had a
lifetime history of at least one other psychiatric disorder.
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Table XI. Lifetime prevalence rates of posttraumatic stress disorder (PTSD)
in several community studies. DSM, Diagnostic and Statistical
Manual of Mental Disorders.
Source Criteria Lifetime prevalence (%)
Helzer et al,
75 1987 DSM-III 1.0
Davidson et al,
76 1991 DSM-III 1.3
Kessler et al,
77 1995 DSM-III-R 7.8
Breslau et al,
78 1995 DSM-III-R 9.2Conclusion
Epidemiology can contribute to resolution of several key
issues. More generally speaking, the epidemiological
methodology is a prerequisite for our knowledge about
how frequent mental disorders are in different countries,
regions,and settings (primary care,schools,hospitals) and
how they vary with time and with other individual and
social and cultural characteristics.Epidemiology is,from
this perspective,important for public health,notably the
planning and harmonizing of health care components in
the European Community,for example.
Epidemiology is also essential for basic and applied
research questions.Clinical and laboratory research can
never answer some questions because of their specific
selection effect of patients,which usually includes a dis-
proportionally high number of more severe complex
cases.Needless to say,such selection effects can modify
the results and may lead to erroneous conclusions about
the effectiveness of one particular intervention or the
mechanisms involved.This is particularly clear for pre-
ventive programs. For instance, we cannot simply use
data from university hospitals,which frequently treat the
most complicated cases,for designing such programs.
23
Perhaps the most fascinating use of epidemiology lies,
however,in the field of causal epidemiology,ie,the iden-
tification of the complex interactions between the vari-
ous pathogenic factors that appear to be responsible for
most forms of mental disorders.Current state-of-the-art
research on mental disorders suggests that the onset—
as well as the whole illness progression—of most forms
of mental disorders,can best be described by a disorder-
specific vulnerability stress model. Given vulnerabili-
ties—either genetically transmitted or learned by social-
ization—come together or interact with specific triggers,
frequently summarized under various stress models
leading to the development of the disorder. In this
respect,epidemiology offers several methods for specif-
ically identifying these critical interactions,such as famil-
ial genetic methods and more complex statistical manip-
ulations (multivariate, discrete survival models) that
require large and unbiased representative data sets.
Despite methodological limitations,lifetime prevalence
rates of PD are remarkably consistent across community
studies and across cultural,racial,and ethnic boundaries.
The exception of higher rates in the NCS may relate to
differences in interview method and the much lower
rates in Taiwan,where lower rates were reported for sev-
eral disorders.Cross-nationally,PD is consistently asso-
ciated with substantial levels of occupational impairment
and is more common among women than men. PD is
highly comorbid with agoraphobia and major depres-
sion.
In contrast to PD, the epidemiological data on agora-
phobia show considerable variation in rates across stud-
ies and cross-culturally.A recent clinical reappraisal of
the ECA data suggests that community studies relying
on the DIS and DSM-IV may have overestimated the
prevalence of agoraphobia without panic.Therefore,the
prevalence estimates from studies such as these should
be regarded with caution until the accuracy of their
prevalence figures on agoraphobia can be more thor-
oughly tested.
The ECA and NCS studies found that prevalence rates
of SP were highest among women, those with less edu-
cation or income, and those who have never been mar-
ried. PTSD and GAD are more prevalent among
women than men. On the basis of community data,
OCD is a much more prevalent disorder than suggested
by previous clinical studies.
Community studies have shown that anxiety disorders
are highly prevalent and important causes of functional
impairment. Data on anxiety disorders are interesting
both for their consistency across quite different settings
and for some of the questions they raise. Further study
is needed to better understand the comorbidity between
anxiety disorders, the consistently higher rates of anxi-
ety disorders in women, and the differential effects of
socioeconomic and cultural factors on PD and phobias.
Further investigation of the complex relationship
between exposure to traumatic events and the develop-
ment of PTSD is needed.
There are three lines of research in epidemiology that
will be of increasing importance in the near future:
•The development of assessment of disability and qual-
ity of life.
• Longitudinal studies of the progression of the symp-
toms,such as early symptoms.
• Familial genetic studies.
Finally,for all of the anxiety disorders,we need epidemio-
logical data to answer basic questions regarding etiology
and prevention,as well as clinical studies to improve treat-
ment and prevent disability caused by these highly preva-
lent disorders. ❏
The epidemiology of anxiety disorders - Martin  Dialogues in Clinical Neuroscience - Vol 5 . No.3 . 2003
295Clinical research
296
Epidemiología de los trastornos de ansiedad: revisión
Los estudios epidemiológicos muestran que los trastornos de ansiedad presentan una elevada prevalen-
cia y son una causa importante de alteraciones funcionales; de hecho constituyen el trastorno mental más
frecuente en nuestra comunidad. Las fobias son el trastorno más comun, siendo la fobia simple y la ago-
rafobia las que presentan las prevalencias más elevadas. El trastorno de pánico y el trastorno obsesivo-
complusivo (OCD) son menos frecuentes (prevalencia a lo largo de la vida de 2%), existiendo datos dis-
cordantes en el caso de fobia social (2%-16%) y el trastorno de ansiedad generalizada (3%-30%). Estos
estudios destacan la importancia de realizar una definición exacta de estos trastornos utilizando criterios
de diagnóstico y de valoración claros que eviten ninguna ambigüedad. La frontera entre los trastornos
de ansiedad está a menudo mal definida y en algunos casos puede variar ampliamente en función de la
definición utilizada. La fobia simple, agorafobia y el trastorno de ansiedad generalizada son más fre-
cuentes en la mujer, mientras que no se observan diferencias significativas entre géneros en el caso de la
fobia social, el trastorno de pánico y OCD. Los trastornos de ansiedad son más frecuentes entre las per-
sonas separadas, divorciadas y viudas; su prevalencia es superior entre los 25 y 44 años e inferior entre los
mayores de 65 años. La edad de inicio de los distintos tipos de trastornos de ansiedad varia ampliamente:
las fobias comienzan en una edad muy temprana, mientras que los trastornos de pánico comienzan en la
adolescencia y juventud. Los estudios clínicos —más que los epidemiológicos—  han examinado los fac-
tores de riesgo, como los acontecimientos de la vida, experiencias de la infancia y factores familiares. Los
trastornos de ansiedad presentan un desarrollo crónico y continuo y aparecen frecuentemente de forma
concomitante con otros trastornos de ansiedad, trastornos depresivos y problemas de toxicomanias. Los
trastornos de ansiedad preceden frecuentemente a los trastornos depresivos o problemas de toxicoma-
nias. El diagnóstico de estas comorbilidades pueden influenciar ciertos factores de riesgo como incapa-
cidad funcional o la calidad de vida. Queda por aclarar si algunos trastornos de ansiedad (por ejemplo el
trastorno de pánico) son factores de riesgo de suicidio. La comorbilidad de los trastornos de ansiedad pre-
senta importantes implicaciones en el momento de la exploración y el tratamiento debiendose además
examinar los factores de riesgo. La etilogía, el desarrollo natural de la enfermedad y la evolución de estos
trastornos requieren una mayor exploración en los estudios epidemiológicos.
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Épidémiologie des troubles anxieux : revue de la littérature
Les études épidémiologiques montrent que les troubles anxieux ont une forte prévalence et sont une cause
importante de handicap fonctionnel ; ils représentent les troubles mentaux les plus fréquents de la collecti-
vité. Les phobies sont les plus courantes avec les taux les plus élevés pour la phobie simple et l’agoraphobie.
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(3 %-30 %) sont discordants. Ces études soulignent l’importance d’une définition exacte des troubles en uti-
lisant des critères diagnostiques et d’évaluation sans ambiguïté. Les limites entre les troubles anxieux sont
souvent mal définies et les cas peuvent considérablement différer selon la définition retenue. La phobie sim-
ple, l’agoraphobie et l’AG sont plus courantes chez les femmes, alors qu’il n’y a pas de différence selon le sexe
pour la PS, les TP et les TOC. Les troubles anxieux sont plus habituels chez les sujets séparés, divorcés et veufs
; leur prévalence est la plus élevée chez les sujets âgés de 25 à 44 ans et la plus faible chez les sujets âgés de
plus de 65 ans. L’âge de début des différents types de troubles anxieux varie largement : les phobies appa-
raissent précocement, alors que le TP apparaît chez l’adulte jeune. Des études cliniques - plus qu’épidémio-
logiques - ont analysé les facteurs de risque, tels que les événements de la vie, les expériences de l’enfance et
les facteurs familiaux. Les troubles anxieux ont une évolution chronique et durable et présentent souvent une
comorbidité avec d’autres troubles anxieux, des troubles dépressifs et l’abus d’une substance. Le plus souvent,
les troubles anxieux précèdent les troubles dépressifs ou l’abus d’une substance. Les diagnostics de comor-
bidité peuvent influer sur les facteurs de risque comme le handicap fonctionnel et la qualité de vie. Le doute
persiste sur la responsabilité de certains troubles anxieux (p. ex. le TP) comme facteurs de risque de suicide.
La comorbidité des troubles anxieux a d’importantes implications pour l’évaluation et le traitement et les fac-
teurs de risque devraient être explorés. Les études épidémiologiques devront  davantage aborder l’étiologie,
l’histoire naturelle et l’évolution de ces troubles. 
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